The world is one step closer to a vaccine for tuberculosis. Picture: David Ritchie/African News Agency (ANA)
The world is one step closer to a vaccine for tuberculosis. Picture: David Ritchie/African News Agency (ANA)

New tuberculosis vaccine shows promising results

By DPA Time of article published Oct 30, 2019

Share this article:

New Delhi - An experimental tuberculosis vaccine has shown

promising results in protecting half the people who received it,

scientists said on Tuesday, marking a potential breakthrough in the

fight against the world's most lethal infectious disease.

About 1.5 million people die of tuberculosis each year, meaning that

even a vaccine with a partial success rate could have major impact.

The results of the trial were reported at a conference in Hyderabad,

India, the country worst-affected by tuberculosis, and published in

the New England Journal of Medicine.

The vaccine, was tested at 11 sites in Kenya, South Africa and Zambia

in over 3 500 HIV-negative adults with latent tuberculosis

infection, pharma giant GlaxoSmithKline said.

Half the adults received two doses of the vaccine and the rest

received placebo shots. Thirteen people in the vaccine group and 26

in the placebo group developed active tuberculosis, it said.

The final results were consistent with the primary analysis done

after two years of follow-up and published last year.

"We are one more cautious, but exciting step, close to a vaccine for

TB," said Paula Fujiwara, scientific director of the International

Union Against Tuberculosis and Lung Disease, which is hosting the

conference.

Experts say additional trials need to be conducted to confirm these

findings in other populations and the vaccine is still a few years

from being licensed.

The current tuberculosis vaccine, the Bacillus Calmette-Guerin (BCG)

jab, created in 1921, is frequently ineffective.

"These results demonstrate that for the first time in almost a

century, the global community potentially has a new tool to provide

protection against TB," Thomas Breuer, chief medical officer of GSK

Vaccines said.

dpa

Share this article:

Related Articles